W E L C O M E !

Our Research

The McFall Lab investigates RAS proteins—molecular switches that control critical proliferative pathways. When these proteins become mutated, they can drive uncontrolled cell growth and contribute to cancer development and progression. Our research takes a comprehensive, systems-based approach to understand how different RAS mutations behave across various cancer types.

We are particularly focused on identifying why some cancers develop resistance to treatment and how we can overcome these challenges. By mapping the complex roles these proteins play within cells, we're working to guide personalized treatment strategies.

Our ultimate goal is to translate our molecular mechanistic insights into better outcomes for patients—offering therapies tailored to patients and their mutations and providing new hope where resistance has limited options.

Our Approach

We utilize a basic science, cell biology-based approach to study RAS biology. Using isogenic cell lines, we isolate the contribution of individual mutations in a controlled genetic background, allowing us to directly compare how different RAS variants alter signaling, cellular behavior, and response to therapeutic intervention.

Our Publications

Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRAS G12R Pancreatic Ductal Adenocarcinoma

It was determined that KRAS G12R is unable to bind key regulators in its signaling pathway, making it possible to target tumors with MEK inhibitors with an autophagy inhibitor. A small study of 8 patients with a G12R mutation were treated with this combination therapy and 5 had progression-free survival of at least six months. One patient had tumor regression by 83% and stayed stable for nearly nine months.

NEWS

Check our some updates!

We would like thank our funding sponsors.